FDA Grants Orphan Drug Designation to Ymmunobio's CEACAM Antibody for the Treatment of Liver Cancer
/PRNewswire/ -- Ymmunobio, a preclinical stage biotech company specializing in the development of innovative treatments for cancer patients, announced today...
Source: prnewswire.com